Investigating factors associated with the progression of native coronary atherosclerosis after PCI

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at investigating factors influencing the progression of native coronary atherosclerosis after percutaneous coronary intervention (PCI).

A cohort of 462 patients was classified into progressive (n = 73) or non-progressive (n = 389) groups according to the presence of native coronary atherosclerosis progression on coronary angiography. Clinical data and angiography results were compared during follow-up, and the time to progression of native coronary atherosclerosis was recorded. Subsequently, multivariate Cox regression analysis was conducted.

In comparison to the non-progressive group, the progressive group had higher levels of glycosylated hemoglobin (HbA1c) and triglycerides (TG), and higher scores on the Synergy Between PCI with Taxus and Cardiac Surgery (SYNTAX) scale, but lower levels of high-density lipoprotein cholesterol. Moreover, the rates of hyperuricemia and acute coronary syndrome (ACS) were higher in the progressive group than the non-progressive group. Multivariate analysis identified ACS, HbA1c level ≥6.5%, TG level ≥5.6 mmol/L, and SYNTAX score ≥23 as risk factors for the progression of native coronary atherosclerosis.

ACS, elevated HbA1c and TG levels, and higher SYNTAX scores may be associated with the progression of native coronary atherosclerosis after PCI.

 

Source:
Journal reference:

Wang, J. & Ling, Z. (2024). Identifying Risk Factors for Native Coronary Atherosclerosis Progression After Percutaneous Coronary Intervention. Cardiovascular Innovations and Applications. doi.org/10.15212/CVIA.2024.0033.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Beyond the anti-obesity benefits of glucagon-like peptide-1 drugs